Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
Safarnezhad Tameshkel F, Karbalaie Niya MH, Zamani F, Motamed N, Ajdarkosh H, Vafaeimanesh J, Khoonsari M, Sohrabi MR, Aten S, Azarkeivan A, Eslami MS, Perumal D, Maadi M, Ghanbari B, Keyvani H.
Safarnezhad Tameshkel F, et al. Among authors: vafaeimanesh j.
Arch Virol. 2020 Oct;165(10):2193-2203. doi: 10.1007/s00705-020-04728-x. Epub 2020 Jul 8.
Arch Virol. 2020.
PMID: 32638116